Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers (A58996) - R8 - Effective July 11, 2024

Date Posted: November 14, 2024

This Local Coverage Article (LCA) has been revised under contractor numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, and NMI), and 01312 (NV).

Effective Date: July 11, 2024

Summary of Changes:

Under Article Text added verbiage, "Mantle Cell Lymphoma" to the Indicated Uses and Limitations box. Under ICD-10 Codes that Support Medical Necessity Group 2: Codes added C83.10, C83.11, C83.12, C83.13, C83.14, C83.15, C83.16, C83.17, C83.18, and C83.19. This revision is effective for 7/11/2024.

Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.

Last Updated Nov 14 , 2024